Together our findings unveil a previously unknown role for GSK3β and ERK1 (Fig. 8A) as phospho-regulators of HTT at membranes (Fig. 8B), shedding new light on the pathogenic mechanisms underlying HD and offering a promising highly druggable pathway for therapeutic intervention that can be inhibited by already available small molecules. Here, MAPK3 is linked to Huntington disease.